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Abstract
Lymphatic ﬁlariasis (LF) and onchocerciasis are parasitic nematode infections that are responsible for a major disease burden in the Afri-
can continent. Disease symptoms are induced by the immune reactions of the host, with lymphoedema and hydrocoele in LF, and der-
matitis and ocular inﬂammation in onchocerciasis. Wuchereria bancrofti and Onchocerca volvulus, the species causing LF and onchocerciasis
in Africa, live in mutual symbiosis with Wolbachia endobacteria, which cause a major part of the inﬂammation leading to symptoms and
are antibiotic targets for treatment. The standard microﬁlaricidal drugs ivermectin and albendazole are used in mass drug administration
programmes, with the aim of interrupting transmission, with a consequent reduction in the burden of infection and, in some situations,
leading to regional elimination of LF and onchocerciasis. Co-endemicity of Loa loa with W. bancrofti or O. volvulus is an impediment to
mass drug administration with ivermectin and albendazole, owing to the risk of encephalopathy being encountered upon administration
of ivermectin. Research into new treatment options is exploring several improved delivery strategies for the classic drugs or new antibi-
otic treatment regimens for anti-wolbachial chemotherapy.
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Introduction
The major forms of human ﬁlarial nematode infections that
may lead to severe pathology are lymphatic ﬁlariasis (LF)
caused by Wuchereria bancrofti and Brugia spp., and oncho-
cerciasis caused by Onchocerca volvulus. LF can present as
recurrent debilitating fevers, lymphangitis, hydrocoele and
lymphoedema [1,2]. Onchocerciasis can present as severe
dermatitis or visual impairment [3,4]. Severe morbidity from
these diseases hinders the development of communities in
developing countries [5–7]. Combined, LF and onchocerciasis
are responsible for the loss of 6.3 million disability-adjusted
life years (disease burden for a population calculated as the
years of life lost owing to death or disability as compared
with a population living without disease and disability [8]) [9].
In Africa, an estimated 406 million people are at risk for LF
and another 102 million are at risk for onchocerciasis [1,2].
Here, we review the major ﬁlarial infections of humans in
Africa, describing the biology of the parasites and the associ-
ated pathologies that develop as a result; current treatments
aimed at eliminating the diseases by breaking the transmis-
sion cycle of the parasites, including co-endemicity with loia-
sis, which interferes with the treatment of onchocerciasis;
and two consortia funded by the Bill and Melinda Gates
Foundation that aim to increase the efﬁcacy of current treat-
ment regimens and to discover new treatments targeting the
essential Wolbachia endosymbionts of LF and onchocerciasis.
Biology of LF, Onchocerciasis and Loiasis
LF is caused by the most disﬁguring parasitic nematodes in
humans: W. bancrofti, Brugia malayi and Brugia timori. Whereas
brugian ﬁlariasis is frequent in Southeast Asia, W. bancrofti is
the only species causing swelling of the legs and male genita-
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lia in Africa. The parasite life cycles include a sexually dimor-
phic adult stage that occurs in the lymphatic system of the
human host. After maturation, the adults produce thousands
of ﬁrst-stage larvae (microﬁlariae (MF)). W. bancrofti MF are
present in the peripheral blood during the night. This evolu-
tionary aspect of periodicity is an adaptation to the biting
behaviours of mosquitoes of the genera Aedes, Anopheles,
Culex and Mansonia. The vectors take up MF during blood
meals, allowing the ﬁlariae to undergo two further moults
into the infective L3 stage for transmission to a new, ﬁnal
host [10].
Unlike in LF, in onchocerciasis the white, hair-like adult
worms live coiled in subcutaneous or deeper intramuscular
tissues surrounded by a ﬁbrous capsule. Within this nodule,
the MF are born and migrate through subcutaneous, conjunc-
tival and intraocular tissues. They can live for several months
before being taken up by the intermediate host for their mo-
ulting into the infective L3 larval stage. Six sibling species of
the Simulium damnosum sensu lato complex are the vectors of
O. volvulus in West Africa. Most Simulium species lay their eggs
attached to rocks and vegetation submerged in highly oxygen-
ated stretches of rivers and streams, where larval and pupal
stages develop. The ﬂight range of Simulium is up to 12 km,
and transmission areas are therefore linked to the breeding
sites, giving the common disease name ‘river blindness’ [10].
Loa loa is conﬁned to Africa in an area spanning from
Benin to Gabon (Fig. 1). Prior to ivermectin treatment, it
was considered to be only a nuisance infection, because of
the lack of debilitating phenotypes [11]. The adult worms
migrate freely through the subcutaneous tissues, occasionally
crossing superﬁcially through subconjunctival tissues, where
they can be easily observed. This manifestation resulted in
the colloquial name ‘tropical eye worm’, but this should not
be confused with the disease caused by O. volvulus, where
MF invade deeper eye tissues. MF of L. loa are taken up by
the day-biting species of the genus Chrysops, commonly
known as mango or deer ﬂies [10].
Because all ﬁlariae reproduce sexually, and larvae require
passage through the intermediate host, or vector, any
increase in adult worm burden necessarily implies re-expo-
sure to infective third-stage larvae. Other ﬁlarial infections,
caused by Mansonella spp. and Diroﬁlaria spp., will not be dis-
cussed in this review.
Clinical Manifestations
The above-mentioned ﬁlarial species differ in the pathologies
that they induce, according to the different tissue tropism of
their life-cycle stages. Bancroftian ﬁlariasis is characterized by
lymphoedema (elephantiasis; Fig. 2a) or hydrocoele (swelling
of the scrotal area), involving dilatation of the lymphatic vessels
and extravasation of ﬂuid from the vessels into surrounding
tissues [12]. It is thought that a chronic immune stimulus
FIG. 1. Map of estimated prevalence of Loa
loa history in Africa, based on survey data col-
lected in more than 4700 villages in 11 coun-
tries.
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caused by incoming larvae (a considerable percentage of which
will die) that develop into adult worms, dying adult worms
themselves and degenerated embryos and larvae released from
fecund adult female worms leads to low-level but constant
triggering of innate and adaptive immune cascades, with associ-
ated angiogenesis and lymphangiogenesis of parasitized
vessels (induced by vascular endothelial growth factors
[13–16]). In addition to actual worm molecules, Wolbachia
endosymbionts also trigger the innate and adaptive immune
system [17–21] and seem to play a major role in this process,
as depletion of Wolbachia by antibiotics precedes a reduction
of these factors and leads to improvement of lymphatic
pathology [15,16]. Both pathologies develop progressively, but
only a minority of affected individuals will develop the most
severe form. There is clear evidence for pathogenesis being a
genetic trait [22–26], and genetic polymorphism in vascular
endothelial growth factors are associated with disease
states [23].
The disﬁguring LF pathology is mainly caused by the adult
stage of the worm, in contrast to onchocerciasis, where
pathology is linked to the microﬁlarial stage. The main pathol-
ogy and disease symptoms, such as keratitis, chorioretinitis
and various forms of dermatitis, are caused by migration of
MF through the skin and the eye after their release from adult
worms residing in subcutaneous nodules. In endemic areas,
onchocercal disease is an important factor in higher mortality
and economic loss [5,7]. As with LF, there is a genetic trait
for the development of an extreme form of pathology, the so-
called hyper-reactive or Sowda form, affecting <5% of infected
individuals [27], which is characterized by a strong Th2-medi-
ated immune response, with eosinophils actively destroying
skin MF, with the consequence of severe dermatitis. In con-
trast, in generalized onchocerciasis, high MF loads in the skin
are tolerated, and regulatory immune responses seem to
dominate Th2 responses, both in the peripheral blood [28]
and in the Onchocerca nodules (onchocercomas, Fig. 2b),
where regulatory T-cells can be found [29,30], together with
strong expression of transforming growth factor-b [31] and
prostaglandin E2 [32] in the tissues; in Sowda, the unbalanced
Th2 response creates ectopic follicles in the onchocercomas,
with strong IgE production by B-cells [33].
A typical manifestation of loiasis is the Calabar swelling,
focal regions of angio-oedema most often located in the
extremities [10]. Severity ranges from mild nuisance as the
worm occasionally passes through the conjunctiva of the eye,
to invasion of the central nervous system and coma in indi-
viduals with a high level of microﬁlaraemia who receive antif-
ilarial therapy [11,34].
Treatment and Control—challenges and
New Perspectives
For both LF and onchocerciasis, mass drug administration
(MDA) programmes have been implemented that annually
(a)
(b)
FIG. 2. (a) Bilateral lymphoedema related to lymphatic ﬁlariasis.
(b) Cross-section of an Onchocerca volvulus female. Anti-WSP (wolba-
chia surface protein) stain. h, hypodermis; g, gut; u, uterus; sMF,
stretched microﬁlaria; cMF, coiled microﬁlaria. Black arrow: Wolba-
chia.
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treat the majority of the eligible endemic populations with
drugs that reduce peripheral (blood or skin) MF loads for six
or more months. The aim is to reduce the prevalence of
MF-positive cases to levels at which transmission is no longer
sustained [1,2,35,36].
Globally, three such drugs have been introduced to com-
bat ﬁlariasis: diethylcarbamazine, ivermectin and albendazole.
A single dose of diethylcarbamazine or ivermectin (6 mg/kg
or 150–200 lg/kg, respectively) leads to strong and sus-
tained killing of blood and skin MF. The mode of action of
diethylcarbamazine is still not completely understood, but it
results in the sequestration of MF and their eventual
destruction by the immune system, and is dependent on
inducible nitric oxide synthase and cyclooxygenase [36,37];
ivermectin acts by hyperpolarization of glutamate-sensitive
channels [38], and was recently shown to block the con-
tractile activity of the excretory/secretory vesicle [39]. As a
result, molecules that may modulate the immune response
are not released, leaving the MF undefended in the lymph
nodes. This is important, as the remote killing of MF is
thought to be the main reason why ivermectin, unlike dieth-
ylcarbamazine, does not lead to ocular damage in onchocer-
ciasis, as MF are not destroyed locally. Therefore,
diethylcarbamazine is used neither for MDA against oncho-
cerciasis nor for MDA against LF in Africa in areas where
there is, or there is a risk of, co-endemicity with onchocer-
ciasis or loiasis [36].
Albendazole inhibits the polymerization of worm b-tubulin
and microtubule formation. A single dose of 400 mg
decreases W. bancrofti microﬁlaraemia for 6–12 months, and
when it is used in combination with ivermectin (or diethyl-
carbamazine), the numbers of MF in LF are reduced for
longer times than after a single dose of ivermectin. Although
higher doses may have effects on adult W. bancrofti, it is not
clear whether the low 400-mg dose would work synergisti-
cally with diethylcarbamazine against adults [36,40,41]. As
ivermectin is not adulticidal, this question does not arise for
onchocerciasis. Questions of whether there is a synergistic
effect on MF killing in onchocerciasis and whether there is
an adulticidal effect of albendazole against adult L. loa worms
need to be studied. Thus, of the three standard drugs used
to treat ﬁlarial infections, diethylcarbamazine, ivermectin and
albendazole, only the latter two are used in MDA pro-
grammes against LF and onchocerciasis in Africa.
For LF, MDA activities are performed through the Global
Programme to Eliminate Lymphatic Filariasis, launched by the
Global Alliance to Eliminate Lymphatic Filariasis (GAELF;
http://www.ﬁlariasis.org/), made up of more than 80 govern-
mental and non-governmental organizations in endemic and
non-endemic (supporter) countries. The GAELF supports the
WHO-recommended strategy of yearly administration of
ivermectin and albendazole in Africa (and diethylcarbamazine
and albendazole in areas outside Africa). During 2009, the
Global Programme to Eliminate Lymphatic Filariasis substan-
tially increased mass drug distribution campaigns in 53 of the
81 countries endemic for LF (Fig. 3), and in 2010, at the
annual meeting of the GAELF held in Seoul, participants cele-
brated South Korea as the second country in which LF con-
trol measures had eliminated the disease [42,43]. However,
with 9 years until the proposed goal of eliminating LF by
2020, it is mainly African countries in which MDA has, for
different reasons, not yet begun or is still severely behind
schedule [2]. Owing to their lack of strong adulticidal activi-
ties, the ivermectin and albendazole are inferior to diethyl-
carbamazine and albendazole, and this may account for the
slower progress in areas where multiple rounds of MDA
have been performed without achieving the expected out-
come [44,45]. In addition, MDA programmes have not been
implemented in many areas where loiasis is endemic, as
administration of ivermectin has led to encephalopathy in
patients co-infected with L. loa, correlating with MF load in
the spinal ﬂuid [34,46,47].
For onchocerciasis, several programmes and developments
have greatly improved the situation in Africa since the 1970s,
when the Onchocerciasis Control Programme in West
Africa was initiated. The Onchocerciasis Control Programme
relied exclusively on vector (Simulium) control by insecticide
spraying in its early years. Following the availability of iver-
mectin from 1987 onwards, the Onchocerciasis Control Pro-
gramme transitioned to become a drug distribution
programme with annual MDA in 11 countries. Onchocercia-
sis Control Programme activities ofﬁcially ended in 2002, but
were continued by the African Programme for Onchocercia-
sis Control (APOC; http://www.who.int/apoc/en/), which
coordinates community-directed distribution of ivermectin
MDA in 28 African countries [1] (Fig. 4).
Although the Onchocerciasis Control Programme and the
APOC have had success in many endemic countries in
reducing parasite infection intensities and onchocerciasis
rates, other than an end to funding in 2015 there is no real
endpoint set for the APOC. Although MDA might eliminate
onchocerciasis in selected areas with ivermectin (alone, or
combined with vector control) [3,48], MDA in the remaining
endemic African countries must be maintained for many
years beyond 2015 [49,50]. This is mainly because of iver-
mectin’s good activity against the MF that cause disease in
the skin and eye. However, it does not kill O. volvulus adult
worms (or only kills them to a small extent), and after a few
months these resume MF production to levels high enough
for transmission to uninfected persons by black ﬂies to
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occur. Currently, APOC activities are focused on mesoen-
demic to hyperendemic areas, i.e. those where disease risks
are highest. Hypoendemic areas, where <30% of the adult
population has palpable onchocermas, receive no interven-
tion. These areas are not disease-free, and may serve as res-
ervoirs for re-introduction of the parasite into previously
Ongoing interventions Not required interventions
Non-endemic countriesInterventions not started
Stopped interventions
FIG. 4. Distribution and status of preventive chemotherapy for lymphatic ﬁlariasis, worldwide, 2009. Note: The distribution of lymphatic ﬁlariasis
is focal in many countries. For the detailed epidemiological situation in countries, please refer to World Health Organization. Preventive chemo-
therapy and transmission control databank. Geneva: WHO, 2010. Available at: (last accessed January 2009).
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controlled areas after the end of interventions. Therefore, in
order to meet the recently formulated goal of onchocerciasis
elimination [1], the APOC must also include hypoendemic
areas, a goal that may require adapting the current strategies
for delivery of MDA for hypoendemic areas.
These new strategies, which may include more effective
drugs or alternative dosing schedules for MDA against
onchocerciasis, could also reduce the number of years
needed to interrupt transmission in previously mesoendemic/
hyperendemic areas. Improved treatments should also make
it feasible to extend MDA into areas that are currently not
being helped, e.g. those that are co-endemic for loiasis. Only
then might the global elimination of onchocerciasis become
an achievable goal [3].
Two major constraints to the success of MDA with the
currently available ivermectin and albendazole in Africa are
that they do not permanently sterilize adult female worms
and there is no clear macroﬁlaricidal effect at the doses cur-
rently in use. Therefore, repeated rounds of MDA for
onchocerciasis have to be employed for many years, owing
to the longer worm lifespan (up to 14 years) [49,50]. How-
ever, if the Wolbachia endosymbionts, which are present for
W. bancrofti and O. volvulus (but not in L. loa), are targeted
with doxycycline, it has been shown that all treated female
worms are sterilized for more than 2 years after treatment,
suggesting permanent sterilization [36,51–53]. More impor-
tantly, 2 years after doxycycline treatment, a large majority
of the worms had died (onchocerciasis, 70% as documented
by histology [54,55]; LF, 90% as documented by ultrasonog-
raphy and antigen test [16,56]). The long time to death of
such sterilized worms is actually an advantage, as the slow
death does not lead to the severe adverse reactions seen
with fast-acting macroﬁlaricidal drugs such as suramin [57].
These features make anti-wolbachial chemotherapy (mostly
together with ivermectin in Africa or diethylcarbamazine in
other areas) the treatment option of choice for individuals
who visit their general practitioner for relief of symptoms
(LF, reversal of lymphatic pathology or even its prevention if
there is a family history; onchocerciasis, dermatitis), as
reviewed in more detail in [36]. However, the downsides
are the contraindications for doxycycline in children <9 years
of age and in pregnant or breast-feeding women, and the
comparatively long treatment duration (4 weeks in LF, and
5–6 weeks in onchocerciasis, as opposed to a single dose of
ivermectin/albendazole every 3 months for approximately
5 years until infection has resolved). This currently restricts
distribution in MDA settings, although it has been shown, in
a community trial involving almost 13 000 individuals in Cam-
eroon, that a 6-week doxycycline regimen can be imple-
mented with a 97.5% compliance rate [47].
Perspectives
How are more effective drugs or dosing schedules for MDA
in LF and onchocerciasis currently being investigated? The
Bill and Melinda Gates Foundation is funding two consortia:
(i) Death to Onchocerciasis and Lymphatic Filariasis (DOLF),
coordinated by Washington University School of Medicine,
St Louis, to improve current treatment regimens with drugs
already used for MDA (http://www.dolf.wustl.edu/); and (ii)
Anti-Wolbachia (A-WOL), coordinated by the Liverpool
School of Tropical Medicine, to further develop the anti-wol-
bachial chemotherapeutic principle in order to shorten treat-
ment durations such that they are compatible with MDA
while retaining the superior beneﬁts of long-term adult
worm sterilization and macroﬁlaricidal efﬁcacy (http://www.a-
wol.net/).
With regard to the ﬁrst, community trials will address
whether annual vs. twice-yearly MDA to eliminate LF, which
is predicted to shorten programme duration from the cur-
rent ﬁve annual MDAs to fewer than three, will have a bet-
ter beneﬁt/cost ratio and thus allow improved planning for
national elimination programmes. In this context, it will also
be investigated whether albendazole without ivermectin
could be used to safely mass treat LF in areas with high loia-
sis co-endemicity. Controlled clinical trials will address the
question of whether higher doses of albendazole together
with ivermectin will have improved efﬁcacy in the long-term
reduction of MF loads in LF in Africa, and whether, for
onchocerciasis, ivermectin/albendazole regimens are superior
to ivermectin alone (the current onchocerciasis MDA regi-
men).
Regarding anti-wolbachial chemotherapy, the principal goal
is the establishment of antisymbiotic chemotherapy directed
against Wolbachia that is compatible with public health con-
trol programmes for human ﬁlariasis. Many thousands of
new and already registered drugs are being screened from
large and focused drug libraries, and promising candidates
are emerging. In addition, to develop improved anti-wolba-
chial chemotherapy within 1–2 years using registered drugs,
ﬁeld trials are under way (http://www.controlled-trials.com;
ISRCTN15216778 and ISRCTN68861628) that combine anti-
biotics that have proven efﬁcacy as single agents, with the
goal of delivering a regimen with a shorter treatment
time, i.e. 2–3 weeks instead of the current 4–6 weeks
[51,54,58]. This will result in a better beneﬁt/cost ratio
and potentially lead to new indications for anti-wolbachial
chemotherapy, such as in areas with suspected ivermectin
resistance or in ‘end-game’ scenarios where the remaining
infected index cases will be actively sought out and
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treated before elimination of the disease is accomplished,
and in restricted areas where loiasis co-infection prevents
the introduction of current MDA strategies, owing to the
risk of severe adverse events. The big advantage is that
permanent sterilization has been proven, so that all individ-
uals who have undergone successful Wolbachia depletion
from their worms will no longer transmit the disease after
completion of a single regimen (unlike the repeated admin-
istration of the classical antiﬁlarial drugs ivermectin and
albendazole for the worms’ lifetime). If more successful
drug candidates emerging from the current screens make
it through the preclinical stage, it should in principle be
possible to deplete Wolbachia in less than a week, with
the outcome already known from the doxycycline studies,
i.e. sterilization and the macroﬁlaricidal effect.
Conclusion
In recent years, more attention has been brought to bear on
eliminating the so-called neglected tropical diseases (NTDs),
of which LF and onchocerciasis are two. This recognition has
brought to the fore the fact that, although human immuno-
deﬁciency virus/AIDS, malaria and tuberculosis kill millions,
about a billion more people are at risk and many more mil-
lions are infected with NTDs, with many being infected with
more than one. Thus, any community/societal development
that would improve the health infrastructure that could help
combat the big three tropical diseases would be hindered if
NTDs were not targeted as well [9,59]. Much of the burden
of NTDs can be found in Africa.
Owing to severe adverse reactions to diethylcarbamazine
in O. volvulus-infected people, treatment of ﬁlarial diseases in
Africa is restricted to ivermectin/albendazole, and this com-
bination has not proven to have good macroﬁlaricidal efﬁ-
cacy. An improved MDA strategy developed by DOLF could
shorten the number of years for which the drugs need to
be administered, and therefore improve the beneﬁt/cost
ratio, but this may not result in the delivery of a macroﬁlari-
cidal regimen, such as proven with antibiotics targeting Wol-
bachia endosymbionts. Therefore A-WOL aims to deliver
regimens with (combinations of) anti-wolbachial drugs that
remove Wolbachia from ﬁlarial worms in a much shorter
time than is currently needed with doxycycline. In parallel,
the discovery of novel anti-wolbachials could provide a nar-
row-spectrum drug (i.e. not interfering with other pro-
grammes to reduce the burden of bacterial infections) that
could be introduced to MDA to ﬁnally eliminate ﬁlarial infec-
tions. By shortening the treatment time needed to eliminate
ﬁlariasis in Africa, it will be easier to coordinate this treat-
ment programme with other NTD programmes, bringing
relief to millions and improving their prospects for a higher
standard of life.
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